OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial - Aurora, SK; Dodick, DW; Turkel, CC; DeGryse, RE; Silberstein, SD; Lipton, RB (Cephalalgia, 2010)
et al.